Navigating Different Subtypes of Dry Eye Disease

EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments

EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease

Now Viewing

EP: 3.Navigating Different Subtypes of Dry Eye Disease

EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes

EP: 5.Updating Formularies: Considerations for Dry Eye Disease

EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease

EP: 8.Resource Allocation in the Treatment of Dry Eye Disease

EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease

EP: 10.Annual Health Care Costs of Managing Dry Eye Disease

EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease

EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease

EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease

EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Kabiri discusses the large unmet need for decades of having a consistently formulated prescription product that addresses the evaporative dry eye disease (DED) component. This allows for aligned patient and provider perspectives on outcomes. A recently approved product helps address this need.

Haumschild asks about additional gaps a new DED product could address. Kabiri notes other forms of keratitis can arise from DED, interfere with treatment response, and lack a “bridge” product to rein these in. The new product targeting evaporative DED allows other metrics like corneal staining and tear breakup time to demonstrate improvement at predictable time points. This predictability can promote treatment compliance.

Haumschild asks about key patient challenges around DED diagnosis and access to appropriate treatments. Kabiri notes a growing younger patient demographic with more evaporative DED from digital device use. DED with an evaporative component can lead to secondary keratitis, glaucoma, drop tolerance, and related issues. Though immunomodulators help address inflammation, residual evaporative DED may persist. The recent FDA approval targeting evaporative DED and overall DED offers an exciting new option for this major unmet need.

Parekh also cites a newly approved treatment for a subset of blepharitis patients. Additional pipeline innovations offer promise for comprehensively addressing DED’s unmet needs in the future.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.